X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN GLENMARK PHARMA/
LUPIN
 
P/E (TTM) x 12.9 41.1 31.5% View Chart
P/BV x 2.3 2.5 93.1% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 GLENMARK PHARMA   LUPIN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
LUPIN
Mar-19
GLENMARK PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs930986 94.3%   
Low Rs517720 71.8%   
Sales per share (Unadj.) Rs322.6369.5 87.3%  
Earnings per share (Unadj.) Rs28.513.4 212.5%  
Cash flow per share (Unadj.) Rs39.237.4 104.8%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.0303.7 60.3%  
Shares outstanding (eoy) m282.17452.49 62.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.22.3 97.1%   
Avg P/E ratio x25.463.6 39.9%  
P/CF ratio (eoy) x18.522.8 80.9%  
Price / Book Value ratio x4.02.8 140.8%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,206386,064 52.9%   
No. of employees `00013.717.7 77.6%   
Total wages/salary Rs m18,71831,513 59.4%   
Avg. sales/employee Rs Th6,636.89,453.8 70.2%   
Avg. wages/employee Rs Th1,364.71,782.0 76.6%   
Avg. net profit/employee Rs Th586.1343.0 170.9%   
INCOME DATA
Net Sales Rs m91,031167,182 54.5%  
Other income Rs m9143,640 25.1%   
Total revenues Rs m91,945170,822 53.8%   
Gross profit Rs m16,15428,822 56.0%  
Depreciation Rs m3,01910,850 27.8%   
Interest Rs m2,8563,078 92.8%   
Profit before tax Rs m11,19318,534 60.4%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m3,1559,017 35.0%   
Profit after tax Rs m8,0396,066 132.5%  
Gross profit margin %17.717.2 102.9%  
Effective tax rate %28.248.7 57.9%   
Net profit margin %8.83.6 243.4%  
BALANCE SHEET DATA
Current assets Rs m69,887138,536 50.4%   
Current liabilities Rs m32,87961,299 53.6%   
Net working cap to sales %40.746.2 88.0%  
Current ratio x2.12.3 94.1%  
Inventory Days Days8184 97.2%  
Debtors Days Days93112 83.2%  
Net fixed assets Rs m28,892127,516 22.7%   
Share capital Rs m282905 31.2%   
"Free" reserves Rs m51,353136,517 37.6%   
Net worth Rs m51,635137,422 37.6%   
Long term debt Rs m41,41866,417 62.4%   
Total assets Rs m125,954279,494 45.1%  
Interest coverage x4.97.0 70.1%   
Debt to equity ratio x0.80.5 166.0%  
Sales to assets ratio x0.70.6 120.8%   
Return on assets %8.63.3 264.4%  
Return on equity %15.64.4 352.7%  
Return on capital %15.18.9 169.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31759,414 61.1%   
Fx outflow Rs m9,72022,282 43.6%   
Net fx Rs m26,59837,132 71.6%   
CASH FLOW
From Operations Rs m16,48116,660 98.9%  
From Investments Rs m-10,133-32,825 30.9%  
From Financial Activity Rs m-4,6857,441 -63.0%  
Net Cashflow Rs m1,770-8,724 -20.3%  

Share Holding

Indian Promoters % 48.3 46.6 103.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 6.9 11.3 61.1%  
FIIs % 34.4 31.9 107.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   56,727 98,259 57.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  GSK PHARMA  PLETHICO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Jalan Committee Recommendations; US-China Trade Worries; Key Q1FY20 Results and Top Stocks in Action(Pre-Open)

On Thursday, the Indian share markets fell sharply in late trade as US-China trade worries dragged global peers.

Related Views on News

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS